1. 1. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, Jonker AH, Lau LPL, Norstedt I, Rath A, Schuster R, Simelyte E, van Weely S. The importance of international collaboration for rare diseases research: A European perspective. Gene Ther. 2017; 24:562-571.
2. 2. Fidan Ç, Akdur R, Ünver ÇN, Şahin ÖC, Alper AB. The two essential components of a comprehensive rare disease control program. 6th International and 24th National Congress on Public Health. 2022. https://uhsk.org/2022/davet/ (accessed August 16, 2023).
3. 3. Taruscio D, Capozzoli F, Frank C. Rare diseases and orphan drugs. Ann Ist Super Sanità. 2011; 47:83-93.
4. 4. de Vrueh R, Baekelandt ERF, de Haan JMH. Priority medicines for Europe and the world: a public health approach to innovation. WHO Background Paper 6.19. Rare Diseases. 2013.
5. 5. U.S. Food and Drug Administration. Orphan Products: Hope for People With Rare Diseases. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/orphan-products-hope-people-rare-diseases (accessed May 12, 2023).